Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States.
Gordan LN, Bensimon AG, Mu F, Kim N, Wu B, Lin D, Paner A, Fowler J, Marshall A, Van Sanden S, Ammann E, Goble J, Zhang X, Le HH, Min EE, Garrison LP Jr.
Gordan LN, et al. Among authors: garrison lp jr.
J Med Econ. 2025 Dec;28(1):910-920. doi: 10.1080/13696998.2025.2514909. Epub 2025 Jun 14.
J Med Econ. 2025.
PMID: 40495704
Free article.